These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 32450807)

  • 1. Immunogenicity and protective efficacy of a live, oral cholera vaccine formulation stored outside-the-cold-chain for 140 days.
    Xian TH; Sinniah K; Yean CY; Krishnamoorthy V; Bahari MB; Ravichandran M; Prabhakaran G
    BMC Immunol; 2020 May; 21(1):29. PubMed ID: 32450807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction and evaluation of V. cholerae O139 mutant, VCUSM21P, as a safe live attenuated cholera vaccine.
    Murugaiah C; Nik Mohd Noor NZ; Mustafa S; Manickam R; Pattabhiraman L
    PLoS One; 2014; 9(2):e81817. PubMed ID: 24505241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges and Considerations in Selecting Animal Models for Evaluating a Live, Cold-Chain-Free, Dual-Use Vaccine (MyChol) for Diarrhoeal Diseases: A Comprehensive Review.
    Tew HX; Subramani P; Chan YY; Nik Mohd Noor NZ; Guruswamy P
    Malays J Med Sci; 2024 Oct; 31(5):41-55. PubMed ID: 39416734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Live, Genetically Attenuated, Cold-Chain-Free Cholera Vaccine-A Research and Development Journey: Light at the End of a Long Tunnel.
    Ravichandran M; Tew HX; Prabhakaran G; Parasuraman S; Norazmi MN
    Malays J Med Sci; 2022 Apr; 29(2):1-7. PubMed ID: 35528817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-O-specific polysaccharide (OSP) immune responses following vaccination with oral cholera vaccine CVD 103-HgR correlate with protection against cholera after infection with wild-type Vibrio cholerae O1 El Tor Inaba in North American volunteers.
    Islam K; Hossain M; Kelly M; Mayo Smith LM; Charles RC; Bhuiyan TR; Kováč P; Xu P; LaRocque RC; Calderwood SB; Simon JK; Chen WH; Haney D; Lock M; Lyon CE; Kirkpatrick BD; Cohen M; Levine MM; Gurwith M; Harris JB; Qadri F; Ryan ET
    PLoS Negl Trop Dis; 2018 Apr; 12(4):e0006376. PubMed ID: 29624592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defining Polysaccharide-Specific Antibody Targets against Vibrio cholerae O139 in Humans following O139 Cholera and following Vaccination with a Commercial Bivalent Oral Cholera Vaccine, and Evaluation of Conjugate Vaccines Targeting O139.
    Kamruzzaman M; Kelly M; Charles RC; Harris JB; Calderwood SB; Akter A; Biswas R; Kaisar MH; Bhuiyan TR; Ivers LC; Ternier R; Jerome JG; Pfister HB; Lu X; Soliman SE; Ruttens B; Saksena R; Mečárová J; Čížová A; Qadri F; Bystrický S; Kováč P; Xu P; Ryan ET
    mSphere; 2021 Aug; 6(4):e0011421. PubMed ID: 34232076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses.
    Shamsuzzaman S; Ahmed T; Mannoor K; Begum YA; Bardhan PK; Sack RB; Sack DA; Svennerholm AM; Holmgren J; Qadri F
    Vaccine; 2009 Feb; 27(9):1386-92. PubMed ID: 19146897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction and characterization of an auxotrophic ctxA mutant of O139 Vibrio cholerae.
    Chan M; Cheong TG; Kurunathan S; Chandrika M; Ledon T; Fando R; Lalitha P; Zainuddin ZF; Ravichandran M
    Microb Pathog; 2010 Nov; 49(5):211-6. PubMed ID: 20558271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine in adults and children in Vellore, South India.
    Raghava Mohan V; Raj S; Dhingra MS; Aloysia D'Cor N; Singh AP; Saluja T; Kim DR; Midde VJ; Kim Y; Vemula S; Narla SK; Sah B; Ali M
    PLoS One; 2019; 14(6):e0218033. PubMed ID: 31211792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial Comparing the Reactogenicity and Immunogenicity of a Single Standard Dose to Those of a High Dose of CVD 103-HgR Live Attenuated Oral Cholera Vaccine, with Shanchol Inactivated Oral Vaccine as an Open-Label Immunologic Comparator.
    Sow SO; Tapia MD; Chen WH; Haidara FC; Kotloff KL; Pasetti MF; Blackwelder WC; Traoré A; Tamboura B; Doumbia M; Diallo F; Coulibaly F; Onwuchekwa U; Kodio M; Tennant SM; Reymann M; Lam DF; Gurwith M; Lock M; Yonker T; Smith J; Simon JK; Levine MM
    Clin Vaccine Immunol; 2017 Dec; 24(12):. PubMed ID: 29021299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Construction and evaluation of a O139 Vibrio cholerae vaccine candidate based on a hemA gene mutation.
    Ravichandran M; Ali SA; Rashid NH; Kurunathan S; Yean CY; Ting LC; Bakar AS; Lalitha P; Zainuddin ZF
    Vaccine; 2006 May; 24(18):3750-61. PubMed ID: 16102875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transient Intestinal Colonization by a Live-Attenuated Oral Cholera Vaccine Induces Protective Immune Responses in Streptomycin-Treated Mice.
    Fakoya B; Sit B; Waldor MK
    J Bacteriol; 2020 Nov; 202(24):. PubMed ID: 32540930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual-Use Vaccine for Diarrhoeal Diseases: Cross-Protective Immunogenicity of a Cold-Chain-Free, Live-Attenuated, Oral Cholera Vaccine against Enterotoxigenic
    Hui Xian T; Parasuraman S; Ravichandran M; Prabhakaran G
    Vaccines (Basel); 2022 Dec; 10(12):. PubMed ID: 36560571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vibriocidal antibody responses to a bivalent killed whole-cell oral cholera vaccine in a phase III trial in Kolkata, India.
    Kanungo S; Lopez AL; Ali M; Manna B; Kim DR; Mahapatra T; Holmgren J; Dhingra MS; Weirzba TF; Nair GB; Bhattacharya SK; Clemens JD; Sur D
    PLoS One; 2014; 9(5):e96499. PubMed ID: 24800828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, immunogenicity, and efficacy of live attenuated Vibrio cholerae O139 vaccine prototype.
    Coster TS; Killeen KP; Waldor MK; Beattie DT; Spriggs DR; Kenner JR; Trofa A; Sadoff JC; Mekalanos JJ; Taylor DN
    Lancet; 1995 Apr; 345(8955):949-52. PubMed ID: 7715293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the protective efficacy of Vibrio cholerae ghost (VCG) candidate vaccines in rabbits.
    Eko FO; Schukovskaya T; Lotzmanova EY; Firstova VV; Emalyanova NV; Klueva SN; Kravtzov AL; Livanova LF; Kutyrev VV; Igietseme JU; Lubitz W
    Vaccine; 2003 Sep; 21(25-26):3663-74. PubMed ID: 12922096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction of novel vaccine strains of Vibrio cholerae co-expressing the Inaba and Ogawa serotype antigens.
    Lebens M; Karlsson SL; Källgård S; Blomquist M; Ekman A; Nygren E; Holmgren J
    Vaccine; 2011 Oct; 29(43):7505-13. PubMed ID: 21807059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral immunization with a probiotic cholera vaccine induces broad protective immunity against Vibrio cholerae colonization and disease in mice.
    Sit B; Zhang T; Fakoya B; Akter A; Biswas R; Ryan ET; Waldor MK
    PLoS Negl Trop Dis; 2019 May; 13(5):e0007417. PubMed ID: 31150386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers.
    García L; Jidy MD; García H; Rodríguez BL; Fernández R; Año G; Cedré B; Valmaseda T; Suzarte E; Ramírez M; Pino Y; Campos J; Menéndez J; Valera R; González D; González I; Pérez O; Serrano T; Lastre M; Miralles F; Del Campo J; Maestre JL; Pérez JL; Talavera A; Pérez A; Marrero K; Ledón T; Fando R
    Infect Immun; 2005 May; 73(5):3018-24. PubMed ID: 15845509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination.
    Tacket CO; Cohen MB; Wasserman SS; Losonsky G; Livio S; Kotloff K; Edelman R; Kaper JB; Cryz SJ; Giannella RA; Schiff G; Levine MM
    Infect Immun; 1999 Dec; 67(12):6341-5. PubMed ID: 10569747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.